跨国药企三季报密集披露，多家企业上调今年业绩指引

新京报

11/01

近期各大药企密集披露今年三季度报告，目前已有包括强生、罗氏、默沙东、礼来等在内的8家跨国药企披露业绩，按总收入计算，JNJ" target="_blank" web="1">强生以696.3亿美元位居榜首；以制药业务收入排名，礼来以458.9亿美元位列第一，其减肥明星药替尔泊肽大卖248亿美元。得益于前三季度业绩增长，多家跨国药企上调今年业绩指引。　　今年全球“药王”宝座竞争激烈　　凭借明星药的...

网页链接

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/hans/news/2580441089"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2580441089\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2580441089?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":false,"pubTime":"2025-11-01 12:06","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2580441089","market":"hk","top_or_hot":-1,"title":"跨国药企三季报密集披露，多家企业上调今年业绩指引","media":"新京报","content":"<div>\n<p>近期各大药企密集披露今年三季度报告，目前已有包括强生、罗氏、默沙东、礼来等在内的8家跨国药企披露业绩，按总收入计算，JNJ\" target=\"_blank\" web=\"1\">强生以696.3亿美元位居榜首；以制药业务收入排名，礼来以458.9亿美元位列第一，其减肥明星药替尔泊肽大卖248亿美元。得益于前三季度业绩增长，多家跨国药企上调今年业绩指引。　　今年全球“药王”宝座竞争激烈　　凭借明星药的...</p>\n\n<a href=\"http://finance.eastmoney.com/a/202511013552468662.html\">网页链接</a>\n\n</div>\n","source":"stock_eastmoney","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>跨国药企三季报密集披露，多家企业上调今年业绩指引</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n跨国药企三季报密集披露，多家企业上调今年业绩指引\n</h2>\n\n<h4 class=\"meta\">\n\n\n2025-11-01 12:06 北京时间&nbsp;&nbsp;&nbsp;<a href=http://finance.eastmoney.com/a/202511013552468662.html><strong>新京报</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>近期各大药企密集披露今年三季度报告，目前已有包括强生、罗氏、默沙东、礼来等在内的8家跨国药企披露业绩，按总收入计算，JNJ\" target=\"_blank\" web=\"1\">强生以696.3亿美元位居榜首；以制药业务收入排名，礼来以458.9亿美元位列第一，其减肥明星药替尔泊肽大卖248亿美元。得益于前三季度业绩增长，多家跨国药企上调今年业绩指引。　　今年全球“药王”宝座竞争激烈　　凭借明星药的...</p>\n\n<a href=\"http://finance.eastmoney.com/a/202511013552468662.html\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU2112291526.USD","symbol_name":"BGF WORLD HEALTHSCIENCE \"A4\" (USD) INC","start_time":0,"source_url":"http://finance.eastmoney.com/a/202511013552468662.html","article_id":"2580441089","we_media_id":null,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202511013552468662.html","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2580441089","pubTimestamp":1761970012,"columns":[],"sourceInfo":{"source_id":"stock_eastmoney","name":"东方财富"},"weMediaInfo":null,"summary":"近期各大药企密集披露今年三季度报告，目前已有包括强生、罗氏、默沙东、礼来等在内的8家跨国药企披露业绩，按总收入计算，强生以696.3亿美元位居榜首；以制药业务收入排名，礼来以458.9亿美元位列第一，其减肥明星药替尔泊肽大卖248亿美元。得益于前三季度业绩增长，多家跨国药企上调今年业绩指引。今年全球“药王”宝座竞争激烈凭借明星药的热销，“药王”宝座竞争激烈。","collect":0,"end_time":0,"defaultTopTitle":"eastmoney.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"LU2112291526.USD":"BGF WORLD HEALTHSCIENCE \"A4\" (USD) INC","IE0002141913.USD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I2\" (USD) ACC","LU1267930813.SGD":"FRANKLIN TEMPLETON SHARIAH GLOBAL EQUITY \"AS\" (SGD) ACC","MRK":"默沙东","IE00BJJMRZ35.SGD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I2\" (SGDHDG) ACC","IE0034235303.USD":"PINEBRIDGE US RESEARCH ENHANCED CORE EQUITY \"A\" (USD) ACC","LU2471134952.CNY":"INVESCO GLOBAL EQUITY INCOME ADVANTAGE \"A\" (CNYHDG) INC","LU1934455863.HKD":"AB SICAV I LOW VOLATILITY TOTAL RETURN EQUITY PORT \"A\" (HKD) ACC","LU1023059063.AUD":"BGF WORLD HEALTHSCIENCE \"A2\" (AUDHDG) ACC","IE00BFTCPJ56.SGD":"Janus Henderson Global Life Sciences A Acc SGD","LU2361044865.SGD":"WELLINGTON US QUALITY GROWTH \"A\" (SGDHDG) ACC","LU0640476718.USD":"THREADNEEDLE (LUX) US CONTRARIAN CORE EQ \"AU\" (USD) ACC","LU2129689605.HKD":"FRANKLIN GLOBAL INCOME \"A\" (HKD) INC","LU0466842654.USD":"HSBC ISLAMIC GLOBAL EQUITY INDEX \"A\" (USD) ACC","LU0070302665.USD":"FRANKLIN MUTUAL U.S. VALUE \"A\" (USD) ACC","LU2471134523.USD":"INVESCO GLOBAL EQUITY INCOME ADVANTAGE \"A\" (USD) ACC","LU0882574055.USD":"富达全球健康医疗A ACC","LU1280957306.USD":"THREADNEEDLE (LUX) US CONTRARIAN CORE EQUITIES \"AUP\" (USD) INC","IE00B1BXHZ80.USD":"Legg Mason ClearBridge - US Appreciation A Acc USD","LU1261432733.SGD":"Fidelity World A-ACC-SGD","LU0861579265.USD":"联博低波幅策略股票基金A","LU1974910355.USD":"Allianz Thematica Cl AMg DIS USD","LU1935042991.SGD":"MANULIFE GF GLOBAL MULTI-ASSET DIVERSIFIED INCOME  \"AA\" (SGDHDG) INC","LU2430703095.HKD":"WELLINGTON MULTI-ASSET HIGH INCOME \"AM4\" (HKD) INC","BMS":"碧美斯","LU0432979614.USD":"JPM GLOBAL HEALTHCARE \"A\" ACC","LU1221951129.SGD":"NORDEA 1 STABLE RETURN \"HM\" (SGDHDG) INC","LU0792757196.USD":"TEMPLETON SHARIAH GLOBAL EQUITY FUND \"A\" (USD) ACC","LU0058720904.USD":"联博国际健康护理基金A","LU1244550577.SGD":"FTIF - Franklin Global Multi-Asset Income A (Mdis) SGD-H1","IE00BVYPNW00.USD":"GUINNESS GLOBAL EQUITY INCOME \"C\" (USD) ACC","LU2468319806.SGD":"MANULIFE GF HEALTHCARE \"AA\" (SGDHDG) ACC","LU1989772840.SGD":"CPR Invest - Climate Action A2 Acc SGD-H","LU0203345920.USD":"SCHRODER ISF QEP GLB ACT. VL \"A\" (USD) ACC","LU1066051225.USD":"HSBC GIF GLOBAL EQUITY VOLATILITY FOCUSED \"AC\" (USD) ACC","LU1941712348.USD":"ALLIANZ PET AND ANIMAL WELLBEING \"AT\" (USD) ACC","LU0006306889.USD":"SCHRODER ISF US LARGE CAP \"A\" (USD) INC AV","LU1037948897.HKD":"AB LOW VOLATILITY EQUITY PORTFOLIO \"AD\" (HKD) INC","LU0345770993.USD":"NINETY ONE GSF GLOBAL STRATEGIC EQUITY \"A\" (USD) INC","BK4559":"巴菲特持仓","LU1430594728.SGD":"Eastspring Investments - Global Low Volatility Equity AS SGD","BK4592":"伊斯兰概念","LU0211331839.USD":"FRANKLIN MUTUAL GLB DISCOVERY \"A\" (USD) ACC","LU1196500208.SGD":"NORDEA STABLE RETURN \"HB\" (SGDHDG) ACC","LU1934455277.USD":"AB SICAV I LOW VOLATILITY TOTAL RETURN EQUITY PORT \"AD\" (USD) INC","LU0265550359.USD":"BGF SYSTEMATIC GLOBAL ENHANCED EQUITY YIELD \"A2\" (USD) ACC","LU1917777945.USD":"安联专题基金Cl AT Acc","LU1059921491.USD":"NORDEA 1 GLOBAL STABLE EQUITY \"HB\" (USDHDG) ACC","JNJ":"强生","LU1941712264.USD":"ALLIANZ PET AND ANIMAL WELLBEING \"A\" (USD) INC"},"translate_title":"The third quarterly reports of multinational pharmaceutical companies are intensively disclosed, and many companies have raised their performance guidance for this year","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"BMS":1,"JNJ":0.89,"MRK":0.9},"content_text":"近期各大药企密集披露今年三季度报告，目前已有包括强生、罗氏、默沙东、礼来等在内的8家跨国药企披露业绩，按总收入计算，JNJ\" target=\"_blank\" web=\"1\">强生以696.3亿美元位居榜首；以制药业务收入排名，礼来以458.9亿美元位列第一，其减肥明星药替尔泊肽大卖248亿美元。得益于前三季度业绩增长，多家跨国药企上调今年业绩指引。　　今年全球“药王”宝座竞争激烈　　凭借明星药的热销，“药王”宝座竞争激烈。作为礼来业绩增长主力的双靶点重磅降糖/减肥药替尔泊肽，今年前三季度的销售额已经超越默沙东明星药“K药”帕博利珠单抗（233.03亿美元），大卖248.4亿美元，业内预期该药有望冲击今年全球“药王”。　　默沙东的“K药”是近几年全球最畅销的PD-1单抗，获批适应症超30项，于2023年问鼎“药王”，并在2024年蝉联销冠。从今年上半年销售业绩来看，诺和诺德的司美格鲁肽、K药、替尔泊肽之间的差距并不大，K药已经被司美格鲁肽赶超，替尔泊肽紧追其后。　　今年前三季度，K药的销售收入增势已趋缓，当前已被替尔泊肽赶超。而诺和诺德尚未发布今年的三季报，其王牌降糖/减肥药司美格鲁肽的销售额尚未披露，能否稳当销冠尚不得而知。　　据礼来披露的三季报，今年前三季度，礼来实现营收458.9亿美元，替尔泊肽成为其营收的主力贡献产品。其中，Mounjaro（降糖版替尔泊肽）今年第三季度销售额为65.15亿美元，同比增长109%，前三季度销售额为155.56亿美元，同比增长94%； Zepbound（减重版替尔泊肽）第三季度销售额为35.88亿美元，同比增长185%，前三季度销售额达到92.81亿美元，同比增长达207.52%。 　　新京报记者整理　　强生、罗氏等上调全年业绩指引　　已发布三季报的8家跨国药企中，强生、罗氏、默沙东的总营收排前三名，分别为696.3亿美元、548.8亿美元、486.1亿美元。若以制药业务板块的营收来排名，礼来、强生、默沙东分别位列前三名，分别为458.9以美元、446.4亿美元、433亿美元。　　得益于替尔泊肽等明星药热卖，今年前三季度，礼来成为8家披露三季报的跨国药企中，制药业务收入最高的企业。在今年半年报中，礼来上调了2025年业绩预期，预计全年营收为600亿美元至620亿美元。三季报中，礼来再次上调了业绩预期，预计全年收入在630亿美元到635亿美元。　　位列总营收TOP1的强生，今年前三季度创新制药和医疗科技分别实现营收446.4亿美元、236.7亿美元，同比分别增长4.7%、5.6%。其肿瘤类产品依然是强生最大的收入来源，如达雷妥尤单抗、阿帕他胺、西达基奥仑赛等产品增势强劲。其中，强生与传奇生物合作开发的明星CAR-T细胞疗法西达基奥仑赛今年前三季度实现13.32亿美元销售额，成功迈入“十亿美元分子”行列。随着三季报业绩出炉，强生也上调了全年营收预期，预计全年收入将增长4.8%-5.3%，达到930亿美元-934亿美元。　　以总营收排在第二位的罗氏，其制药业务板块的收入为355.55亿瑞士法郎（约425.5亿美元），同比增长9%；其中，中国区销售额实现了9%的同比增长，成为全球增长的重要引擎之一。制药业务方面，乳腺癌治疗药物Phesgo（帕妥珠单抗曲妥珠单抗皮下注射制剂）销售额强势增长54%，罗氏诊断板块的业务收入为103亿瑞士法郎，同比增长1%。基于前三季度业绩，罗氏也上调了今年全年业绩预期。　　总营收排在第三位的默沙东今年前三季度实现营收486.1亿美元，其中制药业务实现营收433亿美元，曾经的药王“K药”销售收入233.03亿美元，同比增长8%，增势已趋缓。其全球首创HIF-2α抑制剂Welireg实现4.96亿美元的销售额，同比增长达42%。另一款王牌产品HPV疫苗Gardasil/Gardasil 9的前三季度销售额大幅下滑40%至42.02亿美元。不过，默沙东去年6月新上市的21价肺炎球菌结合疫苗Capvaxive表现强劲，今年前三个季度实现4.8亿美元的销售额，超出市场预期。受前三季度业绩影响，默沙东将2025年营收指引下调3亿美元，预计全球销售额将在645亿美元至650亿美元之间，但小幅上调全年每股收益预期至最高8.98美元。　　百时美施贵宝（BMS）虽然今年前三季度营收微降1%至356.9亿美元，但其多个产品增长出色，如阿达格拉西（Krazati）2025年前三季度累计收入1.49亿美元，同比增长72%。Opdualag（纳武利尤单抗+瑞拉利单抗）实现营收8.35亿美元，同比增长24%。CD19 CAR-T疗法Breyanzi实现9.66亿美元销售额，同比增幅高达100%。全球首个红细胞成熟剂罗特西普前三季度销售额同比增长35%至16.61亿美元。基于增长产品的出色表现，BMS上调了2025年收入指引至475亿美元-480亿美元。　　得益于专业药品和疫苗业务的强劲表现，葛兰素史克今年第三季度表现超出预期，营收为85亿英镑，同比增长7%，实现扭亏为盈；今年前三季度营收为240.5亿英镑（约323.3亿美元）。葛兰素史克也上调了公司全年指引，营业额增长指引上调至6%至7%，核心营业利润上调至9%至11%，每股收益上调至10%至12%。　　诺华、赛诺菲则均是重申2025年全年的业绩预期指引。其中，诺华预计全年销售额将实现高个位数增长和低两位数核心运营利润增长预期。赛诺菲预计全年固定汇率下高个位数百分比销售增长，并预计业务每股收益将强劲反弹，增长率达低双位数百分比。（文章来源：新京报）","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"}}}